Biofrontera Inc. 8K

Biofrontera Inc. announced strong Q2 and first-half 2026 results with significant revenue and margin improvement, a sharply reduced net loss, and progress toward cash flow breakeven, supported by Ameluz growth and post-transaction cost efficiencies despite an ITC-related lamp exclusion order.

Biofrontera Inc. reported strong financial results for the quarter and six months ended June 30, 2026, highlighted by 32.9% year-over-year growth in Q2 net product revenue to $12.0 million, gross margin expansion to 80% driven by a lower Ameluz cost structure post its October 2025 strategic transaction with Biofrontera AG, and a sharply reduced Q2 net loss of $0.6 million with Adjusted EBITDA near breakeven. Management attributed performance to a restructured cost base, disciplined commercial execution, and increasing Ameluz demand, noting some Q2 order pull-forward ahead of an International Trade Commission exclusion order on the RhodoLED XL lamp effective July 7, 2026, which is not expected to affect full-year revenue goals as the company pursues a remediation plan. For the first half of 2026, revenue rose 25.4% to $22.1 million, operating cash use fell to $1.7 million (including a $3.7 million related-party payable paydown tied to the strategic transaction), and net loss narrowed to $5.4 million, while cash and equivalents stood at $4.7 million and total liabilities at $18.1 million, including $4.6 million of convertible notes maturing in November 2027. The company also highlighted progress in its pipeline, including a PDUFA date in late September 2026 for Ameluz in superficial basal cell carcinoma with a planned launch in Q1 2027 if approved, and positive clinical data in additional dermatologic indications, while reiterating its aim to reach cash flow breakeven in 2026.

Filing Facts

CIK

1858685

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-037610

Alert Tier

6